Investigation on Potential Correlation Between the RNA-Binding Protein of Evolutionarily Conserved MEX3 Family and Non–Small-Cell Lung Cancer

Ming Zhang, Hualiang Zhang, Linfeng Cao, Guoxin Hou, Chao Lü, Zhixian Fang, Xiaodong Lv, Jingjing DengResearch 2021 · DOI

Introduction

Non-Small-Cell Lung Cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, characterized by significant genetic heterogeneity and complex clinical outcomes. While primary oncogenic drivers are well-documented, the role of post-transcriptional regulation—specifically how cells manage mRNA stability and translation—is an emerging area of interest. The MEX3 (muscle excess 3) family, consisting of four evolutionarily conserved RNA-binding proteins (MEX3A–D), represents a unique class of regulators. These proteins possess both RNA-binding domains and a RING finger domain, conferring E3 ubiquitin ligase activity. This dual functionality allows them to influence cellular processes by simultaneously modulating gene expression and protein degradation. This study investigates the expression patterns, prognostic value, and immunological correlations of the MEX3 family in NSCLC.

Methodology

This research employed a comprehensive bioinformatic meta-analysis across several high-powered public databases:

  • Genomic Analysis: The COSMIC database was utilized to assess somatic mutations and copy number variations (CNV) within the MEX3 gene family.
  • Expression Profiling: mRNA levels in cancerous versus healthy lung tissues were compared using the Oncomine™ database.
  • Survival Analysis: The Kaplan-Meier Plotter was used to correlate MEX3 expression levels with Overall Survival (OS) in a cohort of thousands of patients.
  • Immune Infiltration: The Tumor Immune Estimation Resource (TIMER 2.0) tool was applied to evaluate the relationship between MEX3 expression and the infiltration of immune cells, such as T cells, B cells, and macrophages, into the tumor microenvironment.

Results and Discussion

Genomic Stability and Overexpression

Analysis of the COSMIC database revealed that the MEX3 genes are remarkably stable; they rarely undergo significant somatic mutations or copy number changes in NSCLC. Instead, the primary driver of malignancy appears to be overexpression. In NSCLC tissues, MEX3A, B, and D were significantly upregulated compared to normal controls. For instance, MEX3A expression showed a 1.937-fold increase in Lung Adenocarcinoma (LUAD) ($P = 9.11 \times 10^{-14}$), suggesting that the overabundance of these proteins, rather than structural mutations, contributes to tumor progression.

Prognostic Significance

The study identified a strong correlation between high MEX3 expression and poor clinical outcomes. In the general NSCLC population, high expression of MEX3A, B, and D was associated with significantly lower Overall Survival.

  • MEX3A: Associated with a Hazard Ratio (HR) of 1.48.
  • MEX3B: HR of 1.37.
  • MEX3D: HR of 1.30.

Subtype analysis revealed further specificity. High expression of MEX3A, B, and C served as strong indicators of poor prognosis in LUAD. Conversely, MEX3D emerged as a particularly critical marker for Lung Squamous Cell Carcinoma (LUSC), though it also showed significant prognostic value in LUAD (HR = 2.13, $P = 4.5 \times 10^{-10}$).

The Tumor Immune Microenvironment

Beyond direct tumor growth, the MEX3 family appears to influence the immune landscape. High expression of MEX3A in LUAD was positively correlated with tumor purity but negatively correlated with the infiltration of dendritic cells. This suggests that MEX3 proteins may contribute to an "immune-excluded" or "cold" tumor state, helping cancer cells evade detection and destruction by the host immune system.

Conclusion

The MEX3 family of RNA-binding proteins represents a significant, yet previously underappreciated, factor in the progression of NSCLC. Their consistent overexpression and strong correlation with poor survival across multiple datasets establish them as robust prognostic biomarkers. Furthermore, their potential role in remodeling the immune microenvironment opens new avenues for therapeutic intervention. Future research should focus on "wet lab" validation to elucidate the precise molecular targets of the MEX3 RING domain and explore whether targeting these proteins can enhance the efficacy of current immunotherapies.

Summary updated

Abstract

Abstract Background As mRNA binding proteins, MEX3 (muscle excess 3) family highlights its unique characteristics and plays an emerging role in post-transcriptionally regulating programmed of biological processes, including tumor cell death and immunological relevance. These have been shown to be involved in various diseases, however, the role of MEX3 in non-small-cell lung cancer (NSCLC) has not been fully elucidated. Results In this study, we found that the sequence or copy number of MEX3 gene did not change significantly, which can explain the stability of malignant tumor development through the COSMIC database. Further, gene expression in NSCLC was examined using the Oncomine™ database, and the prognostic value of each gene was analyzed by Kaplan-Meier analysis. The results showed that overexpressed of MEX3A, MEX3B, MEX3C and MEX3D were associated with significantly lower OS in patients with NSCLC and LUAD, while overexpressed of MEX3D was associated with significantly poorer OS in patients with LUSC. We also applied the Tumor Immune Estimation Resource (TIMER) tool to assess the correlations between distinct MEX3 and the infiltrating immune cell landscape. Conclusion On this subject, we have learned about the complexity and heterogeneity of NSCLC through MEX3. We found that most of MEX3 is highly expressed in NSCLC. High expression indicates a poor prognosis and has a certain immune correlation. Therefore, these conclusions can lay a framework for the prognosis of NSCLC patients and the development of treatment strategies in the future.
BibTeX
@inproceedings{zhang2021investigation,
  author = {Ming Zhang and Hualiang Zhang and Linfeng Cao and Guoxin Hou and Chao Lü and Zhixian Fang and Xiaodong Lv and Jingjing Deng},
  title = {{Investigation on Potential Correlation Between the RNA-Binding Protein of Evolutionarily Conserved MEX3 Family and Non–Small-Cell Lung Cancer}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-800392/v1},
}
Figure